SCM-AGH / SCM Lifescience - LARVOL DELTA

A Long-term Safety Follow-up Study of SCM-AGH in Patients Who Completed SCM-APT2001 Study (clinicaltrials.gov) - P=N/A | N=42 | Active, not recruiting | Sponsor: SCM Lifescience Co., LTD.

New trial • Pancreatitis • CRP

Safety and Efficacy of SCM-AGH in Subjects With Moderate to Severe Atopic Dermatitis (clinicaltrials.gov) - P1/2 | N=92 | Completed | Sponsor: SCM Lifescience Co., LTD. | Recruiting ➔ Completed

Trial completion • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Safety and Efficacy of SCM-AGH in Patients With Moderate to Severe Acute Pancreatitis (clinicaltrials.gov) - P1/2 | N=36 | Completed | Sponsor: SCM Lifescience Co., LTD. | Active, not recruiting ➔ Completed | Trial completion date: Jun 2022 ➔ Mar 2022 | Trial primary completion date: Jun 2022 ➔ Jan 2022

Trial completion • Trial completion date • Trial primary completion date • Pancreatitis • CRP • IL6 • TNFA

Safety and Efficacy of SCM-AGH in Patients With Moderate to Severe Acute Pancreatitis (clinicaltrials.gov) - P1/2; N=36; Active, not recruiting; Sponsor: SCM Lifescience Co., LTD.; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed • Pancreatitis • CRP • IL6 • MRI • TNFA

Founder Soon-wook Song, who returned from management of SCM Life Science, re-established R&D identity [Google translation] (businesspost.co.kr) - "SCM Life Sciences CEO Song Soon-wook is accelerating the domestic phase 2 clinical trial to develop SCM-AGH, a stem cell treatment candidate, as a treatment for moderate-to-severe atopic dermatitis, while simultaneously challenging the US phase 2 clinical trial....According to SCM Life Sciences on the 16th, CEO Song changed his business strategy to actively promote the export of new drug candidate materials and accelerated R&D, including clinical trials, before exporting the technology. We decided to pursue a strategy to further increase....Currently, SCM-AGH...is undergoing a phase 2 clinical trial in Korea, and plans to promote a phase 2 clinical trial in the US within 2022."

New P2 trial • Trial status • Atopic Dermatitis

Safety and Efficacy of SCM-AGH in Subjects With Moderate to Severe Atopic Dermatitis (clinicaltrials.gov) - P1/2; N=92; Recruiting; Sponsor: SCM Lifescience Co., LTD.; Trial completion date: Nov 2021 ➔ Dec 2022; Trial primary completion date: Sep 2021 ➔ Jun 2022

Clinical • Trial completion date • Trial primary completion date • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Safety and Efficacy of SCM-AGH in Patients With Moderate to Severe Acute Pancreatitis (clinicaltrials.gov) - P1/2; N=39; Recruiting; Sponsor: SCM Lifescience Co., LTD.; Trial completion date: Sep 2021 ➔ Jun 2022; Trial primary completion date: Jun 2021 ➔ Jun 2022

Clinical • Trial completion date • Trial primary completion date • Pancreatitis • CRP • IL6 • MRI • TNFA

SCM Life Sciences achieves more than half of registration for phase 2 clinical trial for atopic dermatitis [Google translation] (Yakup Shinmoon) - "According to SCM Life Sciences, more than half of the subjects with moderate-to-severe atopic dermatitis required for phase 2 clinical trials have been registered, and domestic clinical trials are proceeding as planned. SCM Life Sciences announced that it has signed a contract with a US clinical trial consignee for US clinical trials of atopic dermatitis stem cell treatment. Since the 27th of last month, SCM Life Sciences has been working on a phase 2 clinical trial in the United States."

Enrollment status • Trial status • Atopic Dermatitis

SCM Life Sciences completes phase 2 clinical trial for atopic dermatitis [Google translation] (Hankyung) - "SCM Life Sciences...has completed a clinical trial initiation meeting (SIV) at 4 local hospitals added for the phase 2 clinical trial (ADT2002) for 'SCM-AGH'....SCM Life Sciences is conducting phase 2 clinical trials at 11 hospitals nationwide, starting with the first administration in February this year. Last month, Kyungpook National University Hospital, Yangsan Pusan ​​National University Hospital, Chosun University Hospital, and Chungnam National University Hospital were added as clinical trial institutions. By completing the SIV for the four hospitals this time, the company expects to get patients faster."

Trial status • Atopic Dermatitis • Dermatology

Long-Term Safety Follow-Up Study of SCM-AGH in Subjects Who Participated and Administered SCM-AGH in to Severe Atopic Dermatitis Clinical Trials (clinicaltrials.gov) - P=N/A; N=92; Enrolling by invitation; Sponsor: SCM Lifescience Co., LTD.; Not yet recruiting ➔ Enrolling by invitation

Clinical • Enrollment open • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

SCM Life Insurance completes the first phase 2 clinical administration of 'SCM-AGH', a treatment for atopic dermatitis [Google translation] (Pharm News) - "On the 16th, SCM Life Science...announced that it has completed the first phase 2 clinical administration of its atopic dermatitis stem cell therapy 'SCM-AGH'....Starting with Inha University Hospital, which completed the first patient administration this time, SCM Life Science is planning to conduct phase 2 clinical trials for 72 patients in 11 hospitals."

Trial status • Atopic Dermatitis

SCM Life Science approved IRB for Phase 2 clinical trial…Patient registration from this month [Google translation] (Hankyung) - "SM Life Science...announced on the 9th that it will start patient registration after obtaining approval from the Institutional Review Board (IRB) for atopic dermatitis stem cell treatment 'SCM-AGH'. According to IRB approval, the company will begin registering patients for phase 2 clinical trials in earnest from this month. Phase 2 clinical trials are conducted in 11 domestic hospitals. The effectiveness of the drug at low doses will be verified, and commerciality will also be confirmed by reviewing production cost and treatment cost reduction. After completing phase 2 clinical trials, Phase 3 clinical trials and domestic sales are handled by Handok..."

Trial completion date • Atopic Dermatitis

Long-Term Safety Follow-Up Study of SCM-AGH in Subjects Who Participated and Administered SCM-AGH in to Severe Atopic Dermatitis Clinical Trials (clinicaltrials.gov) - P=N/A; N=92; Not yet recruiting; Sponsor: SCM Lifescience Co., LTD.; Initiation date: Jul 2020 ➔ Dec 2020

Clinical • Trial initiation date • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Safety and Efficacy of SCM-AGH in Subjects With Moderate to Severe Atopic Dermatitis (clinicaltrials.gov) - P1/2; N=92; Recruiting; Sponsor: SCM Lifescience Co., LTD.; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Atopic Dermatitis • Dermatitis • Dermatology • Dermatopathology • Immunology • Inflammation

Long-Term Safety Follow-Up Study of SCM-AGH in Subjects Who Participated and Administered SCM-AGH in to Severe Atopic Dermatitis Clinical Trials (clinicaltrials.gov) - P=N/A; N=92; Not yet recruiting; Sponsor: SCM Lifescience Co., LTD.; Initiation date: Jan 2020 ➔ Jul 2020

Clinical • Trial initiation date